Poor
Mostly Unaligned
Patient Risk:
Moderate
Summary
Many safety/side-effect claims include specific incidence “up to X%” rates that are not provided in the supplied label excerpts (5.1). Indication claims (melanoma/lung/breast) are unsupported because Indications and Usage (1) text is not included. Mechanism wording is only partially aligned with the supplied 12.1 text.
Category Scores
Accurate Statements
Keytruda can cause hypothyroidism (underactive thyroid).
5.1 Thyroid Disorders: “KEYTRUDA can cause immune-mediated thyroid disorders” and incidence details for hypothyroidism.
Keytruda can cause diarrhea.
5.1 Immune-Mediated Colitis: “colitis, which may present with diarrhea.”
Keytruda can cause rash.
5.1 Immune-Mediated Dermatologic Adverse Reactions: “can cause immune-mediated rash or dermatitis.”
Keytruda can cause pneumonitis.
5.1 Immune-Mediated Pneumonitis: “KEYTRUDA can cause immune-mediated pneumonitis.”
Keytruda can cause colitis (inflammation of the colon).
5.1 Immune-Mediated Colitis: “KEYTRUDA can cause immune-mediated colitis.”
Keytruda can cause hepatitis (inflammation of the liver).
5.1 Hepatotoxicity and Immune-Mediated Hepatitis: “KEYTRUDA can cause immune-mediated hepatitis.”
Keytruda can cause kidney problems.
5.1 Immune-Mediated Nephritis with Renal Dysfunction: “KEYTRUDA can cause immune-mediated nephritis.” (kidney problems is broader phrasing than “nephritis with renal dysfunction.”)
Unsupported Statements
Keytruda (pembrolizumab) is used to treat various types of cancer, including melanoma, lung cancer, and breast cancer.
Indications are not supported by the provided excerpts; Indications and Usage (1) text is not included.
Keytruda (pembrolizumab) is an immunotherapy that works by boosting the body's natural defenses to fight cancer cells.
Partially supported by 12.1 mechanism (PD-1/PD-L1 blockade releasing inhibition of immune response), but not supported in the provided text as “immunotherapy”/“boosting the body's natural defenses.”
Keytruda can cause fatigue.
Fatigue is not mentioned in the supplied label excerpts (12.1/5.1).
Fatigue is reported by up to 40% of patients taking Keytruda.
No fatigue incidence/rate is provided in the supplied label excerpts.
Diarrhea is reported by up to 30% of patients taking Keytruda.
The excerpts state colitis “may present with diarrhea,” but do not provide a diarrhea incidence percentage.
Rash is reported by up to 20% of patients taking Keytruda.
The excerpts provide immune-mediated dermatologic adverse reactions incidence (1.4%), not “rash up to 20%.”
Keytruda can cause itching.
Itching is not mentioned in the supplied label excerpts.
Itching is reported by up to 15% of patients taking Keytruda.
No itching incidence/rate is provided in the supplied label excerpts.
Keytruda can cause nausea and vomiting.
Nausea and vomiting are not mentioned in the supplied label excerpts.
Nausea and vomiting are reported by up to 10% of patients taking Keytruda.
No nausea/vomiting incidence/rate is provided in the supplied label excerpts.
Keytruda can cause blood clotting disorders.
The excerpts do not explicitly support the broader term “blood clotting disorders.” While immune thrombocytopenic purpura is listed, the claim uses wording not present or directly mapped in the excerpts.
Side effects of Keytruda are often manageable with medication and other treatments.
The excerpts describe monitoring and management for specific immune-mediated adverse reactions, but do not support the generalized “often manageable” frequency/overall framing.
Contradictions
Low
AI Statement
Hypothyroidism is a common side effect of Keytruda, occurring in up to 20% of patients.
Label Reference
5.1 Thyroid Disorders: “Hypothyroidism occurred in 8% (237/2799)…;” and “new or worsening hypothyroidism… occurring in… 22%…”.
Important Omissions
No label-supported incidence/rate support for several “up to X%” adverse-event claims (fatigue, diarrhea, rash, itching, nausea/vomiting) is provided or verifiable from the included excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported or unverifiable incidence “up to” percentages may mislead risk expectations; fatigue, itching, nausea/vomiting are not supported by the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Unaligned
Primary Issue
Multiple adverse-event claims use specific incidence percentages not supported by the supplied label excerpts, and indication claims are unsupported due to missing Indications and Usage (1).
Suggested Improvement
Remove or rephrase unsupported adverse-event incidence claims (e.g., fatigue/diarrhea/rash/itching/nausea-vomiting “up to X%”) unless exact label-supported rates are provided in the excerpts; avoid indication statements unless Indications and Usage (1) text is included; align wording to the provided 12.1 mechanism language without adding unsupported “boosting natural defenses” phrasing.